Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review

New drugs, including immune checkpoint inhibitors and targeted therapy, have changed the prognosis in a subset of patients with advanced lung cancer, and are now actively investigated in a number of trials with neoadjuvant and adjuvant regimens. However, no phase III randomized studies were publishe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2021-11, Vol.22 (22), p.12244
Hauptverfasser:	Marjanski, Tomasz, Dziedzic, Robert, Kowalczyk, Anna, Rzyman, Witold
Format:	Artikel
Sprache:	eng
Schlagworte:	Anaplastic Lymphoma Kinase - antagonists & inhibitors Anaplastic Lymphoma Kinase - metabolism Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy Clinical trials Diarrhea Diarrhea - chemically induced Drug dosages Epidermal growth factor ErbB Receptors - antagonists & inhibitors ErbB Receptors - metabolism Growth factors Humans Immune checkpoint inhibitors Immunosuppressive agents Immunotherapy Lung cancer Lung diseases Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - surgery Medical prognosis Medical screening Molecular Targeted Therapy - methods Mortality Mutation Nausea - chemically induced Neoadjuvant Therapy - methods Non-small cell lung carcinoma Patient safety Patients Pneumonia Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase receptors Review Skin Surgery Surgical outcomes Systematic review Thorax Toxicity Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!